Record Information |
---|
Version | 5.0 |
---|
Status | Detected and Quantified |
---|
Creation Date | 2006-05-22 15:12:41 UTC |
---|
Update Date | 2021-09-14 15:48:17 UTC |
---|
HMDB ID | HMDB0003208 |
---|
Secondary Accession Numbers | |
---|
Metabolite Identification |
---|
Common Name | Thromboxane |
---|
Description | Thromboxane is a member of the family of lipids known as eicosanoids. It is produced in platelets by thromboxane synthetase, which is produced from the endoperoxides by the cyclooxygenase (COX) enzyme from arachidonic acid. -- Wikipedia ; Thromboxane is a vasoconstrictor, potent hypertensive agent, and facilitates the clumping of platelets. It is in homeostatic balance in the circulatory system with prostacyclin, a related compound. The widely-used drug aspirin acts by inhibiting the ability of the COX enzyme to synthesize the precursors of thromboxane within platelets. -- Wikipedia Thromboxanes are eicosanoids. The eicosanoids consist of the prostaglandins (PGs), thromboxanes (TXs), leukotrienes (LTs), and lipoxins (LXs). The PGs and TXs are collectively identified as prostanoids. Prostaglandins were originally shown to be synthesized in the prostate gland, thromboxanes from platelets (thrombocytes), and leukotrienes from leukocytes, hence the derivation of their names. All mammalian cells except erythrocytes synthesize eicosanoids. These molecules are extremely potent, able to cause profound physiological effects at very dilute concentrations. All eicosanoids function locally at the site of synthesis, through receptor-mediated G-protein linked signalling pathways. |
---|
Structure | CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC InChI=1S/C20H40O/c1-3-5-7-9-11-13-17-20-19(16-14-18-21-20)15-12-10-8-6-4-2/h19-20H,3-18H2,1-2H3/t19-,20+/m0/s1 |
---|
Synonyms | Value | Source |
---|
Thromboxane a2 | HMDB |
|
---|
Chemical Formula | C20H40O |
---|
Average Molecular Weight | 296.531 |
---|
Monoisotopic Molecular Weight | 296.307915902 |
---|
IUPAC Name | (2R,3S)-3-heptyl-2-octyloxane |
---|
Traditional Name | (2R,3S)-3-heptyl-2-octyl-oxane |
---|
CAS Registry Number | 66719-58-2 |
---|
SMILES | CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC |
---|
InChI Identifier | InChI=1S/C20H40O/c1-3-5-7-9-11-13-17-20-19(16-14-18-21-20)15-12-10-8-6-4-2/h19-20H,3-18H2,1-2H3/t19-,20+/m0/s1 |
---|
InChI Key | RZWIIPASKMUIAC-VQTJNVASSA-N |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as thromboxanes. These are eicosanoids structurally characterized by the presence of a 6-member ether containing ring. |
---|
Kingdom | Organic compounds |
---|
Super Class | Lipids and lipid-like molecules |
---|
Class | Fatty Acyls |
---|
Sub Class | Eicosanoids |
---|
Direct Parent | Thromboxanes |
---|
Alternative Parents | |
---|
Substituents | - Thromboxane
- Oxane
- Oxacycle
- Organoheterocyclic compound
- Ether
- Dialkyl ether
- Organic oxygen compound
- Hydrocarbon derivative
- Organooxygen compound
- Aliphatic heteromonocyclic compound
|
---|
Molecular Framework | Aliphatic heteromonocyclic compounds |
---|
External Descriptors | Not Available |
---|
Ontology |
---|
Physiological effect | Not Available |
---|
Disposition | |
---|
Process | |
---|
Role | |
---|
Physical Properties |
---|
State | Solid |
---|
Experimental Molecular Properties | Property | Value | Reference |
---|
Melting Point | Not Available | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | Not Available | Not Available | LogP | Not Available | Not Available |
|
---|
Experimental Chromatographic Properties | Not Available |
---|
Predicted Molecular Properties | |
---|
Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times UnderivatizedChromatographic Method | Retention Time | Reference |
---|
Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022. | 10.89 minutes | 32390414 | Predicted by Siyang on May 30, 2022 | 30.2452 minutes | 33406817 | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 2.7 minutes | 32390414 | AjsUoB = Accucore 150 Amide HILIC with 10mM Ammonium Formate, 0.1% Formic Acid | 42.0 seconds | 40023050 | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 3624.5 seconds | 40023050 | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 1021.5 seconds | 40023050 | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 376.8 seconds | 40023050 | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 590.7 seconds | 40023050 | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 668.0 seconds | 40023050 | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 1377.7 seconds | 40023050 | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 1305.6 seconds | 40023050 | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 122.0 seconds | 40023050 | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 2707.0 seconds | 40023050 | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 790.6 seconds | 40023050 | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 2447.8 seconds | 40023050 | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 1008.4 seconds | 40023050 | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 692.0 seconds | 40023050 | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 925.9 seconds | 40023050 | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 821.8 seconds | 40023050 | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 8.4 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatized |
---|
| GC-MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted GC-MS | Predicted GC-MS Spectrum - Thromboxane GC-MS (Non-derivatized) - 70eV, Positive | splash10-0f9l-6890000000-3f997c71bb65094a1825 | 2017-09-01 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Thromboxane GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Thromboxane GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |
MS/MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Thromboxane 10V, Positive-QTOF | splash10-0002-0090000000-64191400e8b8791d16fb | 2017-09-01 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Thromboxane 20V, Positive-QTOF | splash10-0udj-2590000000-54b3b759c10bf3ea2f7f | 2017-09-01 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Thromboxane 40V, Positive-QTOF | splash10-006x-9640000000-0e1bc8b51f24769887cb | 2017-09-01 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Thromboxane 10V, Negative-QTOF | splash10-0002-0090000000-09bb02afbfa046dee93f | 2017-09-01 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Thromboxane 20V, Negative-QTOF | splash10-0002-1190000000-895c8c2d04b2e1e0853b | 2017-09-01 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Thromboxane 40V, Negative-QTOF | splash10-0ufu-2950000000-96efc7245fc678eba5ae | 2017-09-01 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Thromboxane 10V, Negative-QTOF | splash10-0002-0090000000-2f702178cb616025d7f3 | 2021-09-22 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Thromboxane 20V, Negative-QTOF | splash10-0002-0090000000-3898b4de880fccd3483a | 2021-09-22 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Thromboxane 40V, Negative-QTOF | splash10-0532-1590000000-635fc04338e14fb02a30 | 2021-09-22 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Thromboxane 10V, Positive-QTOF | splash10-0002-3090000000-403f8185d42305f3e7c6 | 2021-09-22 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Thromboxane 20V, Positive-QTOF | splash10-0adm-9240000000-7cc1bf89e8dba2fcce15 | 2021-09-22 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Thromboxane 40V, Positive-QTOF | splash10-0abc-9600000000-a52e9c1820684eb7f306 | 2021-09-22 | Wishart Lab | View Spectrum |
|
---|
General References | - Gurbel PA, Gattis WA, Fuzaylov SF, Gaulden L, Hasselblad V, Serebruany VL, O'Connor CM: Evaluation of platelets in heart failure: is platelet activity related to etiology, functional class, or clinical outcomes? Am Heart J. 2002 Jun;143(6):1068-75. [PubMed:12075265 ]
- Rocca B, Ciabattoni G, Tartaglione R, Cortelazzo S, Barbui T, Patrono C, Landolfi R: Increased thromboxane biosynthesis in essential thrombocythemia. Thromb Haemost. 1995 Nov;74(5):1225-30. [PubMed:8607099 ]
- Dong WG, Liu SP, Zhu HH, Luo HS, Yu JP: Abnormal function of platelets and role of angelica sinensis in patients with ulcerative colitis. World J Gastroenterol. 2004 Feb 15;10(4):606-9. [PubMed:14966927 ]
- van Genderen PJ, Prins FJ, Michiels JJ, Schror K: Thromboxane-dependent platelet activation in vivo precedes arterial thrombosis in thrombocythaemia: a rationale for the use of low-dose aspirin as an antithrombotic agent. Br J Haematol. 1999 Mar;104(3):438-41. [PubMed:10086775 ]
- FitzGerald GA, Oates JA, Hawiger J, Maas RL, Roberts LJ 2nd, Lawson JA, Brash AR: Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man. J Clin Invest. 1983 Mar;71(3):676-88. [PubMed:6338043 ]
- Karamouzis M, Langberg H, Skovgaard D, Bulow J, Kjaer M, Saltin B: In situ microdialysis of intramuscular prostaglandin and thromboxane in contracting skeletal muscle in humans. Acta Physiol Scand. 2001 Jan;171(1):71-6. [PubMed:11350265 ]
- Wacker MJ, Tyburski JB, Ammar CP, Adams MC, Orr JA: Detection of thromboxane A(2) receptor mRNA in rabbit nodose ganglion neurons. Neurosci Lett. 2005 Sep 30;386(2):121-6. [PubMed:15992996 ]
- Pfister SL, Hughes MJ, Rosolowsky M, Campbell WB: Role of contaminating platelets in thromboxane synthesis in primary cultures of human umbilical vein endothelial cells. Prostaglandins Other Lipid Mediat. 2002 Sep;70(1-2):39-49. [PubMed:12428677 ]
- Hsu CY, Halushka PV, Hogan EL, Cox RD: Increased thromboxane level in experimental spinal cord injury. J Neurol Sci. 1986 Jul;74(2-3):289-96. [PubMed:3525758 ]
- Dogne JM, de Leval X, Delarge J, David JL, Masereel B: New trends in thromboxane and prostacyclin modulators. Curr Med Chem. 2000 Jun;7(6):609-28. [PubMed:10702629 ]
- Habib A, Vezza R, Creminon C, Maclouf J, FitzGerald GA: Rapid, agonist-dependent phosphorylation in vivo of human thromboxane receptor isoforms. Minimal involvement of protein kinase C. J Biol Chem. 1997 Mar 14;272(11):7191-200. [PubMed:9054415 ]
- Vericel E, Calzada C, Chapuy P, Lagarde M: The influence of low intake of n-3 fatty acids on platelets in elderly people. Atherosclerosis. 1999 Nov 1;147(1):187-92. [PubMed:10525140 ]
- Conti S, Desideri N, Passaghe S, Castagnoli MN, Cerletti C, Stein ML: Inhibition of thromboxane biosynthesis by 3-pyridinol carboxypentyl ethers substituted with a hydroxylated octyl chain. J Pharm Pharmacol. 1988 Feb;40(2):144-6. [PubMed:2897452 ]
- Ylikorkala O, Makila UM, Viinikka L: Amniotic fluid prostacyclin and thromboxane in normal, preeclamptic, and some other complicated pregnancies. Am J Obstet Gynecol. 1981 Nov 1;141(5):487-90. [PubMed:6895277 ]
- Stuart M, Wu J, Sunderji S, Ganley C: Effect of amniotic fluid on platelet thromboxane production. J Pediatr. 1987 Feb;110(2):289-92. [PubMed:3806304 ]
- Shimura S, Sasaki T, Ishihara H, Satoh M, Masuda T, Sasaki H, Takishima T: [Airway hyperresponsiveness and mucus secretion]. Nihon Kyobu Shikkan Gakkai Zasshi. 1990 Oct;28(10):1299-304. [PubMed:1703251 ]
- Chehrazi BB, Giri S, Joy RM: Prostaglandins and vasoactive amines in cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Stroke. 1989 Feb;20(2):217-24. [PubMed:2465585 ]
- Mello SB, Barros DM, Silva AS, Laurindo IM, Novaes GS: Methotrexate as a preferential cyclooxygenase 2 inhibitor in whole blood of patients with rheumatoid arthritis. Rheumatology (Oxford). 2000 May;39(5):533-6. [PubMed:10852985 ]
- De La Cruz JP, Villalobos MA, Escalante R, Guerrero A, Arrebola MM, Sanchez de La Cuesta F: Effects of the selective inhibition of platelet thromboxane synthesis on the platelet-subendothelium interaction. Br J Pharmacol. 2002 Dec;137(7):1082-8. [PubMed:12429581 ]
|
---|